Burcon NutraScience Reports Fiscal 2026 Results, Shifts to Commercial Execution
Burcon NutraScience Corporation reported fiscal year 2026 results ended March 31, marking a strategic pivot from technology development to commercial execution in plant-based protein.
Burcon NutraScience Corporation reported results for the fiscal year ended March 31, 2026, marking what the company characterizes as a transition from technology development to commercial execution [1]. Chief Executive Officer Kip Underwood described fiscal 2026 as the company's shift toward commercializing its plant-based protein platform [1].
The company, which trades on the Toronto Stock Exchange under ticker and on the OTCQB under ticker , develops plant-based protein technologies [1]. The fiscal year conclusion follows a third quarter ended December 31, 2025, for which Burcon previously reported results [2].
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.